La Revue de medecine interne · 2010
[Recurrent aphthosis: safety of low dose thalidomide].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gil H, Perrin S, Dupond J-L, Meaux-Ruault N, Hafsaoui C, Limat S, Magy-Bertrand N
Аннотация
PURPOSE: Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed.
METHODS: Single-centre non-randomized retrospective open study.
RESULTS: Forty-seven patients were treated with thalidomide for recurrent aphthosis (41 patients) or Behçet disease (six patients). Remission was obtained with a dose of 25 mg daily. Discontinuation of treatment for side effects was not observed in this case series.
CONCLUSION: Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of aphthosis.
METHODS: Single-centre non-randomized retrospective open study.
RESULTS: Forty-seven patients were treated with thalidomide for recurrent aphthosis (41 patients) or Behçet disease (six patients). Remission was obtained with a dose of 25 mg daily. Discontinuation of treatment for side effects was not observed in this case series.
CONCLUSION: Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of aphthosis.